Visa Launches Stablecoin Settlement in the United States, Marking a Breakthrough for Stablecoin Integration
16.12.2025 13:00:00 CET | Business Wire | Press release
With more than $3.5B in annualized stablecoin settlement volume1, Visa brings USDC settlement to U.S. institutions.
Visa Inc. (V) today announced the launch of USDC settlement in the United States, marking a major milestone in the company’s stablecoin settlement pilot program and strategy to modernize its settlement layer underpinning global commerce. For the first time, U.S. issuer and acquirer partners can settle with Visa in Circle’s USDC, a fully reserved, dollar-denominated stablecoin.
With USDC settlement, issuers can benefit from faster funds movement over blockchains, seven‑day availability and enhanced operational resilience across weekends and holidays - without any change to the consumer card experience.
Initial banking participants include Cross River Bank and Lead Bank, which have started settling with Visa in USDC over the Solana blockchain. Broader availability in the U.S. is planned through 2026.
Additionally, Visa is a design partner for Arc, a new Layer 1 blockchain developed by Circle (currently in public testnet). Arc’s purpose-built design offers the performance and scalability needed to help support Visa’s global commercial activity onchain. Visa also plans to utilize Arc for USDC settlement within its network and to operate a validator node once Arc goes live.
“Visa is expanding stablecoin settlement because our banking partners are not only asking about it - they’re preparing to use it,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Financial institutions are looking for faster, programmable settlement options that integrate seamlessly with their existing treasury operations. By bringing USDC settlement to the U.S., Visa is delivering a reliable, bank‑ready capability that improves treasury efficiency while maintaining the security, compliance and resiliency standards our network requires.”
Redefining the modern settlement experience
Visa’s U.S. stablecoin settlement framework features:
- 7-day settlement windows: improving speed and liquidity for banks and fintechs to settle seven days a week instead of the traditional five-business day window
- Modernized liquidity and treasury management: enabling automated, next‑generation treasury operations for bank participants
- Interoperability: bridging traditional payment rails with blockchain‑based infrastructure
Expanding a proven foundation of stablecoin innovation
The introduction of stablecoin settlement in the U.S. continues to build on years of Visa’s active stablecoin settlement pilots across the globe including in several countries within LAC, Europe, AP and CEMEA. As of November 30, Visa’s monthly stablecoin settlement volume passed a $3.5 billion annualized run rate – a significant milestone since Visa became one of the first major networks to settle transactions in a stablecoin in 2023. And in July, Visa announced added support for more blockchains and stablecoins in its stablecoin settlement pilot to give partners more flexibility in how they settle VisaNet obligations.
Visa first experimented with USDC settlement in 2021. Circle, the company behind USDC, emphasized the importance of integrating fully-reserved stablecoins into institutional settlement flows. “Bringing USDC settlement to the U.S. with Visa is a milestone for internet native money moving at the speed of software,” said Nikhil Chandhok, Chief Product and Technology Officer, Circle. “It helps card-issuing financial institutions modernize treasury and unlock new services while retaining the transparency and trust that USDC is known for.”
Early banking partners underscore the benefits of faster, API‑driven settlement experiences. Lead Bank, a technology‑forward community bank working closely with top fintech partners, noted that seven-day settlements and clearer liquidity timing are becoming increasingly important for its clients. “Lead Bank is proud to be among the first U.S. banks to enable USDC settlement with Visa,” said Jackie Reses, CEO, Lead Bank. “This capability brings speed and precision to treasury operations and helps us deliver modern financial services to the communities we serve.”
Cross River Bank, a leading infrastructure provider that offers embedded financial solutions, reinforces the importance of true interoperability. “Fintech and crypto innovators increasingly ask us to bring stablecoins into their existing product suite,” said Gilles Gade, Founder, President and CEO of Cross River. “A unified platform that natively supports both stablecoins and traditional payment networks is the foundation for how value will move globally. As one of the first U.S. banks to enable USDC settlement with Visa, we’re demonstrating how a tech-forward, deeply integrated banking partner can connect blockchain networks and legacy systems at scale.”
To help financial institutions navigate this evolving space, Visa Consulting & Analytics recently launched its Stablecoins Advisory Practice, offering education and strategic guidance on market fit and implementation. Learn more here.
Learn more about USDC settlement here.
About Visa
Visa (NYSE: V) is a world leader in digital payments, facilitating transactions between consumers, sellers, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com.
FAQ
Q: What is Visa’s stablecoin settlement pilot capability in the United States?
- It enables select U.S. issuer and acquirer partners to settle their VisaNet obligations using Circle’s USDC instead of only fiat.
- Settlement occurs on supported blockchains, providing the potential for faster funds movement and greater operational resilience.
Q: What are the advantages of settling with stablecoins?
- Fast movement of funds over the blockchain, including weekends and holidays
- Predictability from a fully reserved, USD‑backed asset
- Collateral reduction consideration for parties that settle 7 days a week.
- Modern treasury and liquidity management: enabling automated treasury operations and simplified reconciliation
Q: Who is this designed for?
- Ideal for financial institutions, fintechs, and others looking to modernize settlement operations, improve liquidity timing, and build programmable money movement experiences.
Q: How is this announcement different from earlier Visa stablecoin news?
- Earlier announcements introduced pilots for stablecoin pre‑funding and payouts for Visa Direct and expanded blockchain support for stablecoin settlement
- Today’s announcement highlights the expansion of Visa’s stablecoin settlement pilot to the U.S., enabling U.S. issuers and acquirers to directly settle Visa obligations in USDC - bringing stablecoins into core settlement operations for U.S. institutional partners.
Q: Do participating issuers and acquirers settle in fiat or stablecoins?
- Participating issuer and acquirer clients can settle in USDC, delivered over supported blockchains.
Q: When will more partners have access?
- Visa is onboarding select U.S. partners now, with broader access expected through 2026. Interested clients are encouraged to engage their account teams.
- Visa continues to lead the evolution of digital payments - bridging the power of blockchain with the reliability and reach of the world’s leading payments network.
Q: Where else is Visa leveraging stablecoin settlement?
- Visa has active stablecoin settlement pilots in several countries within Europe, LAC, AP and CEMEA.
1 As of November 30, 2025
View source version on businesswire.com: https://www.businesswire.com/news/home/20251216483172/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom